GENova appoints Dr. Anders Boegh Jensen to Scientific Advi...( NEW YORK NY Sept. 8 / (OTCBB: GVBP.OB...),Health

NEW YORK, NY, Sept. 8 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - GENova Biotheropeutics, Inc., ("GENova"), a biotechnology company that identifies, acquires, and develops novel drug targets that disrupt the advance of life-threatening diseases, today announced it has appointed Dr. Anders Boegh Jensen to its Scientific Advisory Board (SAB).

Dr. Boegh Jensen will contribute his considerable expertise in biotechnology and molecular biology to GENova's business of identifying, evaluating and developing pioneering research drugs. His expertise is acknowledged by companies such as Pfizer, Amgen, Myriad Genetics, Medarex, and Biogen Idec.

Aaron Whiteman, CEO of GENova, says, "We are delighted to have Mr. Boegh Jensen join the SAB. His credentials and experience in the biotech field will be an asset to GENova as we continue to identify promising cancer-fighting drug patents."

Anders Boegh Jensen, Ph.D.

Anders Boegh Jensen is a biochemist who specializes in biotechnology, genetics and molecular biology. He is currently the Director at Poalis, a plant-based biotechnology company, and serves as an Industrial Representative Board Member at the Danish Society for Biochemistry and Molecular Biology. Dr. Boegh Jensen is also frequently published in leading industry journals such as "Cell". His previous position was Associate Professor at the Institute of Molecular Biology at the University of Copenhagen where he helped modernize biology education and developed advanced Ph.D. courses.

Anders Boegh Jensen's academic credentials include: completion of a Master's thesis at the Institute of Molecular Biology, University of Copenhagen in 1989; a one-year research term at the Carlsberg Research Laboratory; and being awarded a four-year European Union BRIDGE mobility fellowship for his post-graduate research training at the Dept. of Plant Molecular Genetics, CID, CSIC, Barcelona, Spain. He completed hi
'/>"/>